培元抗癌汤联合放化疗对非小细胞肺癌患者临床缓解率及血清鳞状上皮细胞癌抗原和癌胚抗原水平的影响

Effect of Peiyuan anticancer decoction combined with radiotherapy and chemotherapy on clinical remission rate and serum levels of squamous cell carcinoma antigen and carcinoembryonic antigen in patients with non-small cell lung cancer

目的 探讨培元抗癌汤联合放化疗对非小细胞肺癌患者临床缓解率及血清鳞状上皮细胞癌抗原(SCC)和癌胚抗原水平的影响。方法 选取2017年2月至2020年3月在陕西中医药大学附属医院诊治的非小细胞肺癌患者106例,按照随机数字表法分为对照组和观察组,各53例。对照组给予常规放化疗治疗;观察组在对照组基础上给予培元抗癌汤治疗。比较2组临床缓解率、治疗前后血清指标(SCC、癌胚抗原)水平、中医证候积分、生活质量和放化疗期间不良反应发生率。结果 治疗2个化疗疗程后,观察组临床缓解率高于对照组[62.3%(33/53)比30.2%(16/53)],差异有统计学意义(P<0.001)。治疗后,2组血清SCC、癌胚抗原水平均低于治疗前,且观察组均低于对照组,差异均有统计学意义(均P<0.05)。放化疗期间观察组不良反应发生率低于对照组[7.5%(4/53)比24.5%(13/53)],差异有统计学意义(P<0.05)。治疗后,观察组咳嗽、血痰、胸痛、气短、乏力中医证候积分均低于对照组,差异均有统计学意义(均P<0.05)。治疗后2、4、6个月,观察组生活质量Karnofsky评分均高于对照组,差异均有统计学意义(均P<0.05)。结论 培元抗癌汤联合放化疗有利于改善非小细胞肺癌患者疾病进展情况,减少患者血清SCC、癌胚抗原水平和不良反应发生情况,同时改善患者中医证候及生活质量。

Objective To explore the effect of Peiyuan anticancer decoction combined with radiotherapy and chemotherapy on clinical remission rate and serum levels of squamous cell carcinoma antigen(SCC) and carcinoembryonic antigen(CEA) in patients with non-small cell lung cancer. Methods Totally 106 patients with non-small cell lung cancer diagnosed and treated in the Affiliated Hospital of Shaanxi University of Chinese Medicine from February 2017 to March 2020 were selected. Patients were divided into the control group and the observation group according to the random number table method, with 53 cases in each group. The control group was treated with conventional radiotherapy and chemotherapy, and the observation group was treated with Peiyuan anticancer decoction on the basis of the control group. The clinical remission rate, the levels of serum indicators(SCC, CEA), traditional Chinese medicine(TCM) symptom score, quality of life before and after treatment, and the incidence of adverse reactions during radiotherapy and chemotherapy were compared between the two groups. Results After 2 cycles of chemotherapy, the clinical remission rate of the observation group was higher than that of the control group[62.3%(33/53) vs 30.2%(16/53)](P<0.001). After treatment, the levels of serum SCC and CEA in the two groups were lower than those before treatment, and the levels in the observation group were lower than those in the control group(all P<0.05). The incidence of adverse reactions in the observation group was lower than that in the control group[7.5%(4/53) vs 24.5%(13/53)](P<0.05). After treatment, TCM symptom scores such as cough, blood phlegm, chest pain, shortness of breath and fatigue in the observation group were lower than those in the control group(all P<0.05). At 2, 4 and 6 months after treatment, the Karnofsky score of the quality of life in the observation group were higher than those in the control group(all P<0.05). Conclusions Peiyuan anticancer decoction combined with radiotherapy and chemotherapy can improve the progression of non-small cell lung cancer, reduce serum SCC, CEA levels and the occurrence of adverse reactions, and improve the TCM symptoms and quality of life.